Noxopharm partnership with GenesisCare to provide compassionate access to Veyonda

GenesisCare is pleased to announce a clinical alliance with Noxopharm to offer a compassionate access program with Noxopharm’s novel lead product candidate, Veyonda®, for patients with advanced, treatment-resistant, metastatic prostate cancer (mCRPC) being treated with theranostics.

The alliance formalises a program under which Noxopharm has been making Veyonda® available through GenesisCare for compassionate use in combination with 177Lu-PSMA therapy for mCRPC patients in Australia. Following promising clinical outcomes from the compassionate use program and early clinical research, the two companies have formalised an arrangement to make the therapy available for use in patients with few treatment alternatives.

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York.

Professor Nat Lenzo, Clinical Director of Theranostics at GenesisCare and Clinical Professor at Curtin University said: “Prostate cancer is the most common cancer among men in Australia, yet treatment options for advanced metastatic prostate cancer remain limited. Theranostics is offering new hope for late stage prostate cancer patients, many of whom have exhausted conventional treatment options such as chemotherapy. While further studies are required, we are seeing encouraging results from the combination of Lu-PSMA and Veyonda® in select patients requiring additional treatment effects and are grateful for Noxopharm’s support to increase access to this combined therapy for suitable patients.”

Dr Gisela Mautner, Chief Medical Officer of Noxopharm, said: “We are very pleased that Veyonda® has been identified by GenesisCare as a therapy that shows promising early signs of improved outcomes in late stage prostate cancer patients. We look forward to continuing to work closely with GenesisCare to provide Veyonda® on a compassionate use basis for the benefit of patients. Noxopharm will continue to build its research and development program for Veyonda® to document its effects in clinical trials.”

Theranostics is a new field of cancer management utilising Nuclear Medicine. Specially designed molecules are combined with a low dose diagnostic form of radiation to identify cancer location, following diagnosis these same molecules are combined with a more potent therapeutic form of radiation to kill cancer cells. Current uses for this technology include diagnosis/treatment of prostate cancer (177lutetium-177 PSMA therapy, 223radium therapy), thyroid cancer (131iodine therapy), and neuroendocrine tumours (177Lutetium Octreotate therapy).

Veyonda® (Idronoxil) is an experimental oncology drug that may enhance the effects of theranostic treatment with 177Lutetium-PSMA (Lu-PSMA) in men with advanced prostate cancer. Theranostics with LuPSMA combines diagnostic imaging, drug delivery and response monitoring. It has been used as compassionate treatment in more than 3000 patients in Europe and Australia over the past five years and is being studied in several phase II and phase III trials in Australia and around the world. Veyonda® is a novel therapy administered twice daily for 10 days at the time of each Lu-PSMA administration.

The combination of Veyonda® and Lu-PSMA is undergoing evaluation in clinical trials, a recently announced interim analysis in patients with advanced metastatic prostate cancer suggests a very encouraging treatment response rate with a median overall survival of 17.1 months reported in these patients. Additionally, the treatment combination provides a significant reduction in pain following disease progression after conventional treatment while being well tolerated.

For more information on theranostics at GenesisCare please click here

Patient-Doctor-GenesisCare

Related articles

GenesisCare and Ramsay Health Care announce new partnership

Construction Begins on $17m Murdoch Hospital Oncology Facility

Gout medicine found to prevent progression of coronary disease

Notification of MBS changes to Cardiac Imaging Services effective 1st August 2020